Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Hapten Sciences and Particle Sciences are working together to move Hapten’s poison ivy, oak, and sumac therapy into clinical trials. According to Memphis-based Hapten, its injectable small-molecule therapy acts like a vaccine to lessen or eliminate contact dermatitis caused by exposure to urushiol oil in the plants. Particle Sciences will manufacture the therapy, which contains urushiol derivatives, for Phase I/II clinical studies scheduled for this year.
This article has been sent to the following recipient: